Lachaud, whose prior experience focused on international development for animal drugs
, was the European animal health director at ICON Clinical Research in Paris, France from 2000 to 2008.
The Animal Drug
User Fee Act is our best chance to address this challenge, and we will work with them as the bill moves to the Senate floor to ensure that we do not miss this opportunity.
We will work with them to ensure that the Senate includes these provisions in the final Animal Drug
User Fee Act.
The ADUFA legislation, passed in December 2003, created user fees that pharmaceutical companies pay when submitting an animal drug
The Congress, a senior-level B2B conference for animal drug
companies to be held November 27 and 28 in Kansas City, Missouri, showcases innovation in animal health, featuring senior-level speakers from the pharma, biotech, diagnostics and government sectors including Novartis, Merial, the USDA and the FDA.
The company currently owns 54 previously manufactured and marketed Abbreviated New Drug Applications (ANDAs), New Drug Applications (NDAs) and New Animal Drug
Applications (NADAs), more than 100 previously manufactured and marketed prescription and OTC formulations not subject to ANDA approval by the Food and Drug Administration, and a recently renovated 125,000 square foot manufacturing facility.
sales of the animal drug
3-Nitro (Roxarsone), a product used by poultry producers since the 1940s.
The company has submitted a New Animal Drug
Application with the U.
In October 1995, DAHI submitted a New Animal Drug
Application to the U.
In terms of revenue, the global companion animal drug
market is projected to register a healthy CAGR of 4.
In December, animal drug
companies were given three months to decide whether to participate in the voluntary program, which would include new product labels outlining the best uses for products given to food animals in order to reduce anti-microbial resistance.
The Animal Health Institute and the Generic Animal Drug
Alliance announced they had submitted written commitments to FDA, saying they would adhere to the voluntary guidance by removing any claims of growth promotion from their product labels.